TLDR
- ARK Invest bought 1,251,270 shares of Recursion Pharmaceuticals worth $4.33 million
- ARK added 37,075 shares of CRISPR Therapeutics valued at $1.97 million
- ARK sold 566,650 shares of PagerDuty for $3.89 million
- ARK offloaded Teradyne, DraftKings, Twist Bioscience, and Salesforce shares
- The moves show ARK shifting money from tech into biotech
Cathie Wood’s ARK Invest made a series of trades on Wednesday, February 18, 2026. The moves showed a clear pattern: buying into biotech while cutting tech and consumer names.
The biggest buy of the day was Recursion Pharmaceuticals. ARK picked up 1,251,270 shares worth around $4.33 million, adding to a position it has been building for several days.
Recursion Pharmaceuticals, Inc., RXRX
ARK also bought 37,075 shares of CRISPR Therapeutics for about $1.97 million. That purchase continued a steady buildup in the gene-editing company over the past week.
Recursion is known for using artificial intelligence in drug discovery. CRISPR Therapeutics focuses on gene-editing treatments.
ARK Cuts PagerDuty and Teradyne
On the sell side, the largest exit was PagerDuty. ARK sold 566,650 shares worth $3.89 million, continuing a run of reductions in the cloud software company.
ARK also offloaded 11,366 shares of Teradyne for roughly $3.47 million. The semiconductor equipment maker had already seen ARK trimming its position in prior sessions.
Teradyne stock had rallied around 3% following an earnings report earlier in the month. Despite that gain, ARK continued selling.
More Sells Across Consumer and Tech Names
ARK trimmed 103,218 shares of DraftKings for about $2.33 million. The sports betting platform has seen ARK steadily reduce its stake over recent days.
Twist Bioscience saw ARK sell 18,162 shares worth nearly $960,000. That came just one day after ARK sold 119,374 Twist shares valued at $6.31 million on February 17.
Twist stock moved higher after announcing a licensing deal with Invenra, making Twist a co-exclusive provider of a bispecific antibody platform.
ARK also sold 7,662 shares of Salesforce for around $1.41 million. Salesforce closed around 2% higher at $187.79 on Wednesday despite the sale.
The daily trade disclosures are required for ARK’s actively managed ETFs. They show exactly what each fund bought and sold the previous trading day.
The trades show ARK rotating money out of software and tech-adjacent names and putting it into biotech positions it has been growing for at least a week.
Recursion Pharmaceuticals stock was up around 2% on the day. CRISPR Therapeutics gained about 0.66% on the same session.
All seven transactions were disclosed through ARK’s standard daily filing process for February 18, 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
